Category: Medical device company Industry: Drug Manufacturers - Major Quick infos Headquarters: New Brunswick, New Jersey, United States Trade prices Volume: 5.9M Market Cap: 435.09B Prev closed: 150.97 Open: 151.6 High: 153.14 Low: 151.02 52 week low: 109.16 52 week high: 157 Dividends: Next ER: July 21, 2021 Before Market Opens
About the Company
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
Date EPS / Forecast Revenue / Forecast July 21, 2021 April 20, 2021 2.59 / 2.33 22.32B / 22.01B Beat! January 26, 2021 1.86 / 1.82 22.48B / 21.66B Beat! October 13, 2020 2.2 / 1.98 21.08B / 20.2B Beat! July 16, 2020 1.67 / 1.49 18.34B / 17.61B Beat! view more Historical Data
Date Price Open High Low Vol Change ER Jun 18, 2021 161.98 163.27
12.99M -1.96% Jun 17, 2021 165.22 164.28
5.87M 0.48% Jun 16, 2021 164.43 164.71
6.99M -0.04% Jun 15, 2021 164.49 165.37
5.06M -0.53% Jun 14, 2021 165.37 164.50
4.93M 0.25% Jun 11, 2021 164.96 167.07
7.39M -1.27% Jun 10, 2021 167.08 166.00
6.46M 0.90% Jun 9, 2021 165.59 163.99
5.55M 1.35% Jun 8, 2021 163.39 165.28
7.75M -0.88% Jun 7, 2021 164.84 166.00
5.36M -0.68% view more
NYSE - New York Stock Exchange
More profiles and info about the company ISIN: US4781601046 CUSIP: 478160104 Founded: January 1886 Employees: 126,400 News Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020 johnsonandjohnson.gcs-web.com Jul 21, 2020 1:40 am Johnson & Johnson to Participate in Citi ‘Of Hearts and Minds’ Conference Call Series johnsonandjohnson.gcs-web.com Jul 17, 2020 11:30 pm Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa johnsonandjohnson.gcs-web.com Jul 17, 2020 9:00 pm J&J to resume vaccine rollout in Europe following EMA review (updated) seekingalpha.com Apr 21, 2021 12:06 am Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible johnsonandjohnson.gcs-web.com Jun 12, 2021 8:00 pm New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia johnsonandjohnson.gcs-web.com Jun 12, 2021 8:00 pm Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results johnsonandjohnson.gcs-web.com Jun 9, 2021 10:59 pm Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab johnsonandjohnson.gcs-web.com Jun 7, 2021 9:00 pm New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR) johnsonandjohnson.gcs-web.com Jun 3, 2021 Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma johnsonandjohnson.gcs-web.com Jun 1, 2021 10:00 pm Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma johnsonandjohnson.gcs-web.com Jun 1, 2021 9:30 pm Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis johnsonandjohnson.gcs-web.com May 26, 2021 10:00 pm Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients johnsonandjohnson.gcs-web.com May 26, 2021 10:00 pm Johnson & Johnson to Host Live ESG Investor Update Webcast johnsonandjohnson.gcs-web.com May 25, 2021 5:51 am Janssen’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma johnsonandjohnson.gcs-web.com May 25, 2021 European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features johnsonandjohnson.gcs-web.com May 25, 2021 Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease johnsonandjohnson.gcs-web.com May 24, 2021 RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations johnsonandjohnson.gcs-web.com May 22, 2021 3:00 am Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe johnsonandjohnson.gcs-web.com May 21, 2021 10:00 pm IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, FirstLine Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control johnsonandjohnson.gcs-web.com May 20, 2021 JNJ Dividends
Ex-Dividend Amount Announced Date Record Date Payment Date May 24, 2021 1.06 Jun 8, 2021 Feb 22, 2021 1.01 Mar 9, 2021 Nov 23, 2020 1.01 Dec 8, 2020 Aug 24, 2020 1.01 Sep 8, 2020 May 22, 2020 1.01 Jun 9, 2020 view more Key Persons Talk about Johnson below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
If you are looking for News & events, Press Release, they are available on their Investors Relationssite. Homepage: jnj.com
Consensus BUY 100 HOLD 0 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via
Paypal. More features coming soon :) Buy on Amazon
Very few careers can offer you the freedom, flexibility, and income that day trading does. As a day trader, you can live and work anywhere in the world. You can decide when to work and when not to work. You only answer to yourself. That is the life of the successful day trader. Many people aspire to it, but very few succeed.
A Beginner's Guide to Trading Tools and Tactics, Money Management, Discipline and Trading Psychology